TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-550-0780
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3 million
Profitability
Miscellaneous
Employees26
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions
What is TRACON Pharmaceuticals' stock symbol?
TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
How were TRACON Pharmaceuticals' earnings last quarter?
TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. View TRACON Pharmaceuticals' Earnings History.
When is TRACON Pharmaceuticals' next earnings date?
What price target have analysts set for TCON?
2 analysts have issued twelve-month price targets for TRACON Pharmaceuticals' stock. Their predictions range from $7.00 to $9.00. On average, they anticipate TRACON Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 996.0% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.
What is the consensus analysts' recommendation for TRACON Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.
Has TRACON Pharmaceuticals been receiving favorable news coverage?
Press coverage about TCON stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TRACON Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the near future.
Who are some of TRACON Pharmaceuticals' key competitors?
Some companies that are related to TRACON Pharmaceuticals include Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), Idera Pharmaceuticals (IDRA), Applied Genetic Technologies (AGTC), Genocea Biosciences (GNCA), Organovo (ONVO), Cidara Therapeutics (CDTX), Curis (CRIS), Pharmacyte Biotech (PMCB), BioCardia (BCDA), BIONDVAX PHARMA/S (BVXV), Entera Bio (ENTX), Outlook Therapeutics (OTLK) and Vical (VICL).
What other stocks do shareholders of TRACON Pharmaceuticals own?
Who are TRACON Pharmaceuticals' key executives?
TRACON Pharmaceuticals' management team includes the folowing people:
- Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 55)
- Mr. Scott B. Brown, VP & Head of Fin.
- Dr. Sharon Real, Exec. VP of Product Devel. (Age 55)
- Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 42)
- Ms. Suzy Benedict, Sr. VP of Regulatory Affairs
When did TRACON Pharmaceuticals IPO?
(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
Who are TRACON Pharmaceuticals' major shareholders?
TRACON Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.44%) and Nicolet Advisory Services LLC (0.12%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance, Enterprise Associates 14 New and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.
Which major investors are buying TRACON Pharmaceuticals stock?
TCON stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Nicolet Advisory Services LLC. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Cross-Border Opportu Puissance and Enterprise Associates 14 New. View Insider Buying and Selling for TRACON Pharmaceuticals.
How do I buy shares of TRACON Pharmaceuticals?
Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TRACON Pharmaceuticals' stock price today?
One share of TCON stock can currently be purchased for approximately $0.7299.
How big of a company is TRACON Pharmaceuticals?
TRACON Pharmaceuticals has a market capitalization of $21.85 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-34,960,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.
What is TRACON Pharmaceuticals' official website?
How can I contact TRACON Pharmaceuticals?
TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]
MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
